In vitro and in vivo ovarian cancer models combining PARPi with CDK 4/6 showed synergistic effects with palbociclib by inducing HRR deficiency through downregulation of MYC-regulated HR pathway genes, leading to synthetic lethality with olaparib [44]. Here, MYC is linked to ovarian cancer.